Global Systemic Psoriasis Therapeutics Market 2016-2020 - Dominance of Market by Biologics - Key Vendors are AbbVie, Celgene ...
July 25 2016 - 10:02AM
Business Wire
Research and Markets has announced the addition of the "Global
Systemic Psoriasis Therapeutics Market 2016-2020" report to their
offering.
The report forecasts the global systemic psoriasis therapeutics
market to grow at a CAGR of 9.41% during the period 2016-2020.
The report has been prepared based on an in-depth market
analysis with inputs from industry experts. The report covers the
market landscape and its growth prospects over the coming years.
The report also includes a discussion of the key vendors operating
in this market.
One trend resulting in the strong growth of this market is the
advent of biologics with novel MOA and cell-based strategies. This
market is expected to witness the launch of biologic agents that
target the disease pathway specifically, including IL-17/IL-17R
receptor inhibitors. Drugs such as brodalumab, guselkumab, and
tildrakizumab are undergoing Phase III clinical trials.
According to the report, factors such as the dominance of market
by biologics will drive this market's growth prospects for the near
future. Biologics account for over 18% of the global pharmaceutical
sales, outpacing the sales of branded pharmaceuticals. These drugs
will continue to outperform other pharmaceuticals in terms of
product sales as there is an increasing need for innovative
products as effective treatment options for a range of
indications.
Further, the report states that one challenge impeding this
market's growth is the physician's reluctance to prescribe
biosimilars.
Key vendors:
- AbbVie
- Johnson & Johnson
- Celgene
- Amgen
- Pfizer
Key Topics Covered:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Psoriasis: Condition overview
PART 06: Pipeline analysis
PART 07: Market landscape
PART 08: Market segmentation by type of molecule
PART 09: Market segmentation by mechanism of action
PART 10: Market segmentation by severity of disease
PART 11: Market segmentation by ROA
PART 12: Geographical segmentation
PART 13: Market drivers
PART 14: Impact of drivers
PART 15: Market challenges
PART 16: Impact of drivers and challenges
PART 17: Market trends
PART 18: Vendor landscape
PART 19: Appendix
For more information visit
http://www.researchandmarkets.com/research/prqrg8/global_systemic
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160725005757/en/
Research and MarketsLaura Wood, Senior
Managerpress@researchandmarkets.comFor E.S.T Office Hours Call
1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT
Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside
U.S.): +353-1-481-1716Sector: Dermatological Drugs, Psoriasis
Drugs